Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(13%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_3
1
13%
Ph phase_2
6
75%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
6(75.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(4)
Completed(3)
Terminated(1)

Detailed Status

Not yet recruiting3
Completed3
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 26 (75.0%)
Phase 31 (12.5%)

Trials by Status

not_yet_recruiting338%
recruiting113%
completed338%
withdrawn113%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_2

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

NCT04150640
not_yet_recruitingphase_2

A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen

NCT07099794
not_yet_recruitingphase_3

Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

NCT07074353
not_yet_recruitingphase_2

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

NCT07028424
completedphase_2

A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer

NCT04009876
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04150640Phase 2

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Recruiting
NCT07099794Phase 2

A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen

Not Yet Recruiting
NCT07074353Phase 3

Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

Not Yet Recruiting
NCT07028424Phase 2

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

Not Yet Recruiting
NCT04009876Phase 2

A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer

Completed
NCT02551991Phase 2

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Completed
NCT03043547Phase 2

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Completed
NCT02785068Phase 1

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8